Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies.
Cancers (Basel)
; 14(5)2022 Feb 24.
Article
en En
| MEDLINE
| ID: mdl-35267477
Texto completo:
1
Base de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
/
Systematic_reviews
Idioma:
En
Revista:
Cancers (Basel)
Año:
2022
Tipo del documento:
Article
País de afiliación:
Estados Unidos